Clinical Trial of CD40L-Augmented TIL for Advanced Melanoma
Phase 1/2
36
about 4.4 years
18+
1 site in FL
About this study
This trial is testing a single dose of CD40L-augmented TIL in patients with advanced melanoma. Patients will undergo lymphodepletion followed by the TIL product and standard of care interleukin-2.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Cyclophosphamide
- 2.Take Fludarabine
- 3.Take Interleukin-2
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, immunotherapy (Cytokine; stimulates T-cells to proliferate)
infusion
Primary: Phase I: Treatment Emergent Adverse Events (TEAE), Phase II: Objective Response Rate
Secondary: Duration of response, Overall survival, Progression Free Survival (PFS)
Oncology